Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hi-Warble is a Beijing-based biotechnology company that specializes in the development of high-throughput microfluidic platforms for single-cell analysis and precision medicine. The company's core technology focuses on droplet-based microfluidics, which allows for the massive parallel processing of individual cells for applications such as single-cell RNA sequencing and digital PCR. Hi-Warble provides both hardware systems and specialized consumables designed to improve the resolution and efficiency of genomic and proteomic research. Their solutions are utilized by academic researchers and pharmaceutical developers to explore cellular heterogeneity in cancer and immune system disorders. By integrating microfluidics with advanced molecular biology, Hi-Warble aims to provide scalable tools for the next generation of diagnostic and therapeutic discovery.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hi-Warble.